Cancer researchers have unveiled several promising treatment breakthroughs at the annual American Society of Clinical Oncology (ASCO) summit in Chicago, which concluded on Tuesday, highlighting advances that could reshape cancer care in the coming years.
Among more than 7,000 studies presented, one of the most notable developments focused on pancreatic cancer, one of the deadliest forms of the disease and historically resistant to effective treatment advances.
Researchers reported encouraging results from a clinical trial involving a new molecule called daraxonrasib, developed by US-based start-up Revolution Medicines.
The treatment showed significantly improved outcomes compared to standard chemotherapy in patients with an aggressive form of pancreatic cancer.
According to the study, half of the patients treated with daraxonrasib survived more than 13 months — approximately double the survival time observed in the chemotherapy group.
Oncologist Monty Pal described the findings as a major shift in treatment approaches for advanced pancreatic cancer, calling it an “unprecedented paradigm shift.”
The drug works by targeting a protein involved in multiple cancer types, a mechanism that had previously been considered difficult to treat.
Researchers also presented early-stage findings suggesting that widely used weight-loss drugs, including Ozempic and Wegovy, may have broader anti-cancer effects than previously understood.
These GLP-1 receptor agonists, originally developed for diabetes and obesity management, are being studied for potential roles in cancer progression and prevention.
A study examining patients with lung, breast, colorectal and liver cancers found a 38 to 50 per cent reduction in disease progression among those using GLP-1 medications compared with those on conventional diabetes treatments.
However, researchers cautioned that the findings remain preliminary and require confirmation through randomized clinical trials.
Study author Mark Orland noted that the results are “just the start” of further investigation into the possible link between GLP-1 drugs and cancer outcomes.
Other research presented at the summit focused on reducing the intensity of certain cancer treatments to minimise long-term side effects.
One study reassessed axillary lymph node dissection in breast cancer patients, a surgical procedure involving the removal of lymph nodes under the arm.
Findings suggested that omitting the procedure in patients with limited lymph node spread may be safe and could help avoid unnecessary complications.
ASCO Vice President Julie Gralow said the results indicate that the medical community may be overusing some surgical interventions, leading to avoidable long-term side effects.
In prostate cancer research, an international trial highlighted a promising treatment combination for patients with genetic mutations linked to more aggressive disease forms.
The study combined enzalutamide, which blocks hormonal signals that drive tumour growth, with talazoparib, which disrupts cancer cell DNA repair mechanisms.
For patients with the BRCA2 mutation, the combination therapy reduced the risk of disease progression or death by 65 per cent.
Professor Karim Fizazi, who led the study, described the results as “exceptional” and a significant step forward in prostate cancer treatment.
Other studies at the summit explored the role of liquid biopsies and blood-based cancer detection tools, including the Galleri test, which aims to identify early-stage cancers across multiple types.
While some results showed promise, researchers noted that the Galleri test did not demonstrate a clear reduction in late-stage cancer diagnoses across a broad set of cancers in a large UK-based study involving more than 140,000 participants.
Experts said that while early detection research remains promising, further validation is needed before widespread clinical adoption.
Overall, the findings presented at ASCO 2026 reflect a growing shift toward precision medicine, targeted therapies, and less invasive treatment approaches that could improve both survival rates and quality of life for cancer patients.
